{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:00:38Z","timestamp":1780992038899,"version":"3.54.1"},"reference-count":157,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:24:28Z","timestamp":1757543068000},"page":"e299-e314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | The Promise of Immunotherapies in T-Cell Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Colin J.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0001","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5581\/1516-8484.20120013","article-title":"T-cell lymphomas in South America and Europe","volume":"34","author":"Bellei","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"25","key":"10.1016\/j.clml.2025.09.006_bib0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-Cell and natural Killer\/T-Cell Lymphoma Study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0003","first-page":"5","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0004","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hon.2850","article-title":"Cutaneous T-cell lymphomas: an update 2021","volume":"39","author":"Kempf","year":"2021","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.006_bib0006","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0007","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0008","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0009","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0010","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV peripheral T-cell lymphoma: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"issue":"10168","key":"10.1016\/j.clml.2025.09.006_bib0011","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0012","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.006_bib0013","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2025.09.006_bib0014","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.006_bib0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.17117","article-title":"The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma","volume":"192","author":"Scarisbrick","year":"2021","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2025.09.006_bib0016","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Gruppo Italiano Linfomi Cutanei. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.09.006_bib0017","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"10.1016\/j.clml.2025.09.006_bib0018","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2023021786","article-title":"A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas","volume":"144","author":"de Leval","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.09.006_bib0019","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.3390\/cancers13225827","article-title":"Immunotherapy for diffuse large B-cell lymphoma: current landscape and future directions","volume":"13","author":"Modi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0021","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.006_bib0022","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbmt.2008.01.002","article-title":"Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect","volume":"14","author":"Hamadani","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.clml.2025.09.006_bib0023","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.006_bib0024","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clml.2025.09.006_bib0025","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.4049\/jimmunol.0900699","article-title":"Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD\/Shi-scid, IL-2R gamma(null) mice in vivo","volume":"183","author":"Ito","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.006_bib0026","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.09.006_bib0027","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/srep27150","article-title":"Enhancement of anti-STLV-1\/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody","volume":"6","author":"Sugata","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.clml.2025.09.006_bib0029","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0030","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.3324\/haematol.2016.147256","article-title":"Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0031","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0032","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/14737140.2024.2379914","article-title":"Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature","volume":"24","author":"Silva","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0033","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.09.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/7625926","article-title":"Mogamulizumab multimodality therapy with systemic retinoids, interferon, or extracorporeal photopheresis for advanced cutaneous T-cell lymphoma","volume":"2023","author":"Weiner","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clml.2025.09.006_bib0035","doi-asserted-by":"crossref","unstructured":"Ninosu N., Melchers S., Kappenstein M., et al. Mogamulizumab combined with extracorporeal photopheresis as a novel therapy in erythrodermic cutaneous T-cell lymphoma. Cancers (Basel). 2023;16(1):141. doi: 10.3390\/cancers16010141.","DOI":"10.3390\/cancers16010141"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0036","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2024-198022","article-title":"Real-world treatment patterns in patients with adult T-cell leukemia\/lymphoma","volume":"144","author":"Haverkos","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.09.006_bib0037","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.09.006_bib0038","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.09.006_bib0039","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.clml.2025.09.006_bib0040","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2025.09.006_bib0041","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.09.006_bib0042","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.clml.2025.09.006_bib0043","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+ PTCL","volume":"134","author":"Barta","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2025.09.006_bib0044","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.2021011894","article-title":"Phase 1\/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma","volume":"139","author":"Ward","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0045","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0046","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.006_bib0047","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0048","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/blood-2023-182400","article-title":"SGN-35C: a novel CD30-directed antibody-drug conjugate for the treatment of CD30-positive hematologic malignancies","volume":"142","author":"Hamblett","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0049","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.clml.2025.09.006_bib0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.clml.2025.09.006_bib0051","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.09.006_bib0052","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0053","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.09.006_bib0054","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.09.006_bib0055","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0056","first-page":"1265","article-title":"T-PLL-1 protocol of the german CLL Study Group (GCLLSG): a prospective Phase II trial of fludarabine phosphate, mitoxantrone, and cyclophosphamide (FMC) followed by Alemtuzumab consolidation in T-PLL","volume":"29","author":"Hopfinger","year":"2005","journal-title":"Leuk Res"},{"issue":"32","key":"10.1016\/j.clml.2025.09.006_bib0057","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0058","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(15)00227-6","article-title":"Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study","volume":"3","author":"Dumitriu","year":"2016","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0059","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2732.2732","article-title":"Alemtuzumab (Campath-1H) in patients with erythrodermic cutaneous T-cell lymphoma (E-CTCL): the Northwestern University experience","volume":"108","author":"Querfeld","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.09.006_bib0060","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2025.09.006_bib0061","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41375-024-02135-8","article-title":"Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis","volume":"38","author":"Knauft","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0062","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.09.006_bib0063","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.09.006_bib0064","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0065","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0066","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737140.5.1.33","article-title":"Denileukin diftitox: a concise clinical review","volume":"5","author":"Eklund","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2025.09.006_bib0067","unstructured":"Ryan C. FDA approves denileukin diftitox for R\/R cutaneous T-cell lymphoma. OncLive. Published August 8, 2024. Accessed May 31, 2025. Available at: https:\/\/www.onclive.com\/view\/fda-approves-denileukin-diftitox-for-r-r-cutaneous-t-cell-lymphoma."},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0068","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/cas.13513","article-title":"E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma: a phase I study","volume":"109","author":"Ohmachi","year":"2018","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0069","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO-24-01549","article-title":"Efficacy and safety of denileukin diftitox-cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"43","author":"Foss","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.09.006_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody\u2013drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0071","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody\u2013drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.clml.2025.09.006_bib0072","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.clml.2025.09.006_bib0073","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-16-3185","article-title":"Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with S\u00e9zary syndrome","volume":"23","author":"Hurabielle","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.clml.2025.09.006_bib0074","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood-2017-06-792382","article-title":"KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting","volume":"130","author":"Battistella","year":"2017","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.09.006_bib0075","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1200\/JCO.2024.42.16_suppl.7082","article-title":"Lacutamab in patients with relapsed and\/or refractory mycosis fungoides: results from the TELLOMAK phase 2 trial","volume":"42","author":"Pierluigi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0076","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2023-173806","article-title":"Lacutamab in patients with relapsed and refractory S\u00e8zary syndrome: results from the Tellomak phase 2 trial","volume":"142","author":"Bagot","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0077","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0078","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38\u207a immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.09.006_bib0079","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study","volume":"14","author":"Huang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.09.006_bib0081","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"issue":"13","key":"10.1016\/j.clml.2025.09.006_bib0082","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of cutaneous T-cell lymphomas","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0083","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1038\/emm.2014.102","article-title":"Epstein-Barr virus\u2013associated lymphoproliferative diseases: the virus as a therapeutic target","volume":"47","author":"Tse","year":"2015","journal-title":"Exp Mol Med"},{"issue":"17","key":"10.1016\/j.clml.2025.09.006_bib0084","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD-1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.006_bib0086","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0087","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD-1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing l-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0088","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","article-title":"Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"34","author":"Kantekure","year":"2012","journal-title":"Am J Dermatopathol"},{"issue":"12","key":"10.1016\/j.clml.2025.09.006_bib0089","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","article-title":"Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression","volume":"146","author":"Samimi","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0090","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajh.21960","article-title":"Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and S\u00e9zary syndrome","volume":"86","author":"Wada","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0091","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.09.006_bib0092","article-title":"Pembrolizumab in relapsed or refractory mycosis fungoides or s\u00e9zary syndrome","volume":"161","author":"Elghawy","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.clml.2025.09.006_bib0093","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Outcomes of patients with mycosis fungoides and s\u00e9zary syndrome treated with checkpoint inhibitors: a multicenter retrospective analysis","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7683","key":"10.1016\/j.clml.2025.09.006_bib0094","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.clml.2025.09.006_bib0095","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia\u2013lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0096","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s43018-023-00635-7","article-title":"PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma","volume":"4","author":"Wartewig","year":"2023","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.clml.2025.09.006_bib0097","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2025.09.006_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115484","article-title":"Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed\/refractory IIB\/IVB mycosis fungoides\/s\u00e9zary syndrome patients after previous systemic treatment","volume":"222","author":"Stadler","year":"2025","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.09.006_bib0099","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1200\/JCO.2020.38.15_suppl.8049","article-title":"The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL)","volume":"38","author":"Marchi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0100","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/S2152-2650(23)01392-7","article-title":"Updated results of an investigator-initiated phase II study of pembrolizumab and romidepsin for patients with relapsed or refractory T-cell lymphoma (TCL) with survival analysis","volume":"23","author":"Iyer","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0101","doi-asserted-by":"crossref","first-page":"9425","DOI":"10.1182\/blood-2022-170181","article-title":"Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL): preliminary results from the Embolden trial","volume":"140","author":"Roberts","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0102","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/bloodadvances.2024014655","article-title":"Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed\/refractory cutaneous T-cell lymphoma","volume":"9","author":"Querfeld","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0103","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00432-024-05956-3","article-title":"Sintilimab plus GemOx is an effective salvage therapy in patients with refractory\/relapsing nodal peripheral T cell lymphomas","volume":"150","author":"Xiao","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0104","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/bloodadvances.2020002371","article-title":"Pembrolizumab in mycosis fungoides with PD-L1 structural variants","volume":"5","author":"Beygi","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-sirp\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.clml.2025.09.006_bib0106","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.clml.2025.09.006_bib0107","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.09.006_bib0108","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in s\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2025.09.006_bib0109","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","article-title":"Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.09.006_bib0110","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0111","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(21)00271-4","article-title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or s\u00e9zary syndrome: a multicentre, phase 1 study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6382","key":"10.1016\/j.clml.2025.09.006_bib0112","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.clml.2025.09.006_bib0113","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0114","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"26","key":"10.1016\/j.clml.2025.09.006_bib0115","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0116","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.09.006_bib0117","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e14510","article-title":"Preclinical analysis of an autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) immunotherapy for relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL)","volume":"39","author":"Zeng","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.006_bib0118","series-title":"Business Wire","article-title":"Legend Biotech announces FDA clinical hold of its phase 1 clinical trial for LB1901","year":"2022"},{"issue":"19","key":"10.1016\/j.clml.2025.09.006_bib0119","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.3390\/cancers16193430","article-title":"Prevalence and prognostication of CD5+ mature T-cell lymphomas","volume":"16","author":"Elghawy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.clml.2025.09.006_bib0120","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2025.09.006_bib0121","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.006_bib0122","first-page":"1","article-title":"A transgene-encoded truncated human epidermal growth factor receptor (EGFRt) as a safety switch for chimeric antigen receptor (CAR)-T cell therapy","volume":"91","author":"Zhao","year":"2021","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0123","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-024-01094-8","article-title":"Correction: anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0124","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0125","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol Ther"},{"issue":"97","key":"10.1016\/j.clml.2025.09.006_bib0126","doi-asserted-by":"crossref","first-page":"eadn6509","DOI":"10.1126\/sciimmunol.adn6509","article-title":"CD5 deletion enhances the antitumor activity of adoptive T cell therapies","volume":"9","author":"Patel","year":"2024","journal-title":"Sci Immunol"},{"issue":"11","key":"10.1016\/j.clml.2025.09.006_bib0127","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1073\/pnas.76.11.5829","article-title":"Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets","volume":"76","author":"Haynes","year":"1979","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"10.1016\/j.clml.2025.09.006_bib0128","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7\u2013 T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.09.006_bib0129","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1182\/blood.2022017935","article-title":"Selecting CD7\u2013 T cells for CAR T-cell therapy","volume":"140","author":"Themeli","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.09.006_bib0130","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.09.006_bib0131","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/JCO.2024.42.16_suppl.6515","article-title":"Safety and efficacy of CD7-CAR-T cell in patients with relapsed\/refractory T-lymphoblastic leukemia\/lymphoma: phase I dose-escalation\/dose-expansion study","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.09.006_bib0132","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.clml.2025.09.006_bib0133","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0134","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.09.006_bib0135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2025.09.006_bib0136","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.09.006_bib0137","doi-asserted-by":"crossref","unstructured":"Ghobadi A., Aldoss I., Maude S.L., et al. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma: a phase 1\/2 trial. Res Sq. 2024 Aug 5:rs.3.rs-4676375. doi:10.21203\/rs.3.rs-4676375\/v1.","DOI":"10.21203\/rs.3.rs-4676375\/v1"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0138","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","article-title":"Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.clml.2025.09.006_bib0139","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0140","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1182\/blood-2022-158869","article-title":"Updated results and correlative analysis: autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT trial)","volume":"140","author":"Ahmed","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0141","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2022-167504","article-title":"Phase 1 clinical trial of memory-enriched academic HSP-CAR30 for the treatment of relapsed\/refractory Hodgkin lymphoma and CD30+ T-cell lymphoma: clinical and biological studies","volume":"140","author":"Caballero Gonzalez","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0142","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.09.006_bib0143","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/bloodadvances.2023012129","article-title":"CARs for Hodgkin: engine fine-tuning is in order","volume":"8","author":"Grover","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2025.09.006_bib0144","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30 specific chimeric antigen receptor-redirected lymphocytes","volume":"27","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.clml.2025.09.006_bib0145","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","article-title":"Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy","volume":"4","author":"Voorhees","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2025.09.006_bib0146","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.2024026758","article-title":"HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma","volume":"145","author":"Caballero","year":"2025","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2025.09.006_bib0147","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.2023023443","article-title":"T-cell lymphoma: the CAR-T revolution is coming","volume":"143","author":"Grover","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.09.006_bib0148","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous stem-cell transplantation in patients with relapsed or refractory Hodgkin lymphoma: a phase 2 trial","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.clml.2025.09.006_bib0149","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.3390\/cancers13215542","article-title":"CCR4 as a therapeutic target for cancer immunotherapy","volume":"13","author":"Yoshie","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.clml.2025.09.006_bib0150","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","article-title":"Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma","volume":"7","author":"Watanabe","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.09.006_bib0151","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00418-015-1326-2","article-title":"Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs","volume":"144","author":"de Winde","year":"2015","journal-title":"Histochem Cell Biol"},{"issue":"7","key":"10.1016\/j.clml.2025.09.006_bib0152","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.09.006_bib0153","first-page":"1574","article-title":"Targeting T-cell lymphoma using CD70-directed cord blood-derived CAR-NK cells","volume":"142","author":"Rafei","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0154","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.09.006_bib0155","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2025.09.006_bib0156","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","article-title":"TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial","volume":"31","author":"Cwynarski","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.clml.2025.09.006_bib0157","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","article-title":"The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas","volume":"8","author":"Haydu","year":"2024","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025033993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025033993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:43:21Z","timestamp":1780991001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025033993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025033993"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | The Promise of Immunotherapies in T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}